Long-term humoral response following simultaneous Delta and Omicron BA.1 co-infection

Carla Saade, Msc[1], Bruno Pozzetto, MD, PhD[1,2], Melyssa Yaugel Novoa, Msc[1], Bruno Lina, PhD[1,3], Stéphane Paul, PhD[1,2], Antonin Bal, PhD[1,3], Sophie Trouillet-Assant, PhD[1,4] on behalf of Lyon COVID study group*

[1]CIRI - Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Lyon, France.

[2]Immunology laboratory, CIC1408, CHU Saint-Etienne, Saint-Etienne, France

[3]Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004, Lyon, France.

[4]Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, 69310, France

Keywords: SARS-CoV-2 co-infection, long-term immune response, bivalent vaccines

Running title: Delta-BA.1 co-infection immunity

*Study Group team members are listed in the Acknowledgments

Corresponding Author:

Sophie Trouillet-Assant, e-mail: sophie.assant@chu-lyon.fr; address: Hospices Civils de Lyon, France, International Center of Research in Infectiology, Team VirPath, Univ Lyon, Inserm,

21 U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS
22 de Lyon, 69007 Lyon, France. Fax +33-4-72-67- 87-87

23 Alternate author: Carla Saade, e-mail: ext-carla.saade@chu-lyon.fr; address: Hospices Civils
24 de Lyon, France, International Center of Research in Infectiology, Team VirPath, Univ Lyon,
25 Inserm, U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS,
26 UMR5308, ENS de Lyon, 69007 Lyon, France. Fax +33-4-72-67- 87-87

27

Abstract:

To provide insight into the long-term immune response following bivalent vaccines, we sampled vaccinated patients simultaneously co-infected with Delta and BA.1. We reported that simultaneous exposure to the Delta and BA.1 S protein does not confer an additional immune advantage compared to exposure to the Omicron BA.1 S protein alone.

33 Bivalent vaccines containing two different sequences of the Spike (S) protein have been
34 recently approved. A recent study showed that administering a second booster injection
35 using an bivalent vaccine including the S protein of Omicron BA.1 and the ancestral SARS-
36 CoV-2 led 28 days later to an enhanced neutralization capacity against Omicron BA.1, BA.4,
37 and BA.5 compared to administering a monovalent mRNA vaccine to COVID-19-naïve
38 subjects [1]. However, the long-term immunity outcomes of this bivalent vaccine need
39 further investigation, especially given the waning of the humoral response. Others and we
40 have reported cases of simultaneous co-infection by the Delta and BA.1 variants, both have
41 caused major COVID-19 epidemic waves worldwide [2,3]. The present report describes the
42 long-term humoral response of patients co-infected with the variants Delta and BA.1 and
43 aims at providing insights into that induced by bivalent vaccines.

44 We included two groups of fully vaccinated individuals with a breakthrough infection (BA.1
45 in the first group [n=9] and Delta and BA.1 co-infection in the second group [n=9]) as well as
46 a third group of COVID-19-naïve individuals who received three doses of the BNT162b2
47 vaccine (n=9) (Table S1). Blood sampling was performed 6 months after breakthrough
48 infection for infected individuals or after the third vaccine injection for COVID-19-naïve
49 individuals (Table S1). Statistical analyses were performed using the GraphPad Prism®
50 software (version 8; GraphPad software, La Jolla, CA, USA). Participants were included from two
51 clinical studies registered on ClinicalTrial.gov (NCT05060939, NCT04341142). Written informed
52 consent was obtained from all participants and approval was obtained from the regional review
53 board in April 2020 (*Comité de Protection des Personnes Sud Méditerranée I*, Marseille, France;
54 ID-RCB 2020-A00932-37; ID-RCB 2021-A01877-34).

55 There was no significant difference in anti-RBD IgG and anti-S1 IgA levels among individuals
56 with a breakthrough infection caused by Delta and BA.1 or by BA.1 only; however these

57 levels were 4.13 and 10.83 fold lower, respectively, among COVID-19-naïve individuals (Fig.
58 1A and 1B).

59 Neutralizing antibody titers were significantly lower among COVID-19-naïve individuals for
60 all viral variants compared to BA.1-infected and Delta-BA.1-co-infected individuals.
61 Compared to COVID-19-naïve individuals, the median neutralizing antibody titer of BA.1-
62 infected individuals was 8-fold higher for the 19A isolate and 12-fold higher for the BA.5
63 isolate, and it was 8-fold higher for the 19A isolate and 16-fold higher for the BA.5 isolate for
64 Delta-BA.1 co-infected individuals. Interestingly, no significant difference was observed
65 between the two groups of individuals with a breakthrough infection (Fig. 1C).

66 The absence of significant difference in anti-S total antibodies and neutralization capacity
67 between individuals with a single or a dual breakthrough infection would suggest that a
68 simultaneous exposure to the Delta and Omicron BA.1 variants does not confer an additional
69 immune advantage in terms of humoral immunity. Our results suggest that a combined
70 exposure to two different S protein does not confer an immune advantage. In addition, the
71 enhanced humoral response of individuals infected by one or two variants, who were
72 exposed to different S sequences of the one used for vaccination, suggests that this situation
73 confers long-term immune advantages compared to a repeated vaccination with the same
74 sequence of the S protein. Delta-BA.1-co-infected individuals, as well as BA.1-infected
75 individuals, were vaccinated with the wild-type S protein before being infected, which
76 resulted in so-called hybrid immunity. This hybrid immunity has already been shown to
77 induce a more potent long-term immune response against SARS-CoV-2 in comparison to
78 vaccine-induced immunity with the same vaccine[4]. As our series was limited to cases of
79 spontaneous infections with two different variants, studies comparing the long-term

80 immune response induced after a challenge using a monovalent or a bivalent vaccine in

81 COVID-19-naïve individuals are needed to evaluate the true benefit of the second strategy.

82 ***Acknowledgment***. We thank all the staff members of the SARS-CoV-2 testing centre of the
83 Hospices Civils de Lyon who contributed to the sample collection. We thank Cecile Barnel,
84 the Clinical Research Associates, for her excellent work. We thank all the technicians from
85 the virology laboratory whose work made it possible to obtain all these data. We thank all
86 the members of the clinical research and innovation department for their reactivity (DRCI,
87 Hospices Civils de Lyon). We thank Hélène Boyer (DRCI, Hospices Civils de Lyon) for her help
88 in manuscript preparation. We thank all members of the Lyon Covid-ser study group: Jean-
89 Baptiste Fassier, Nicolas Guibert, Dulce Alfaiate, Amélie Massardier-Pilonchery, Vanessa
90 Escuret, Hélène Lozano, Laurence Josset, Bouchra Mokdad, Fanny Joubert and Camille
91 Mena. Lastly, we thank all the participants for their involvement in this clinical study.

92 ***Financial support***. This study has benefited from funding from the *Agence Nationale de*
93 *Recherches sur le Sida et les Hépatites Virales* (ANRS-0154).

94 ***Potential conflicts of interest.*** All authors report no potential conflict of interest.

95 **References**

96 1. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine
97 against Covid-19. New England Journal of Medicine **2022**; 0:null.

98 2. Bal A, Simon B, Destras G, et al. Detection and prevalence of SARS-CoV-2 co-infections
99 during the Omicron variant circulation, France, December 2021 - February 2022. 2022;
100 :2022.03.24.22272871. Available at:
101 https://www.medrxiv.org/content/10.1101/2022.03.24.22272871v1. Accessed 23
102 September 2022.

103 3. Rockett RJ, Draper J, Gall M, et al. Co-infection with SARS-CoV-2 Omicron and Delta
104 variants revealed by genomic surveillance. Nat Commun **2022**; 13:2745.

105 4. Andreano E, Paciello I, Piccini G, et al. Hybrid immunity improves B cells and antibodies
106 against SARS-CoV-2 variants. Nature **2021**;

107 5. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous
108 ChadOx1/BNT162b2 vaccination. Nature **2021**;

109

110 **Figure 1. Humoral immune response 6 months after immunization in individuals**
111 **vaccinated and then co-infected with Delta and BA.1, or vaccinated and then infected with**
112 **BA.1, or in COVID-19-naïve fully-vaccinated individuals**

113 Blood samples were obtained 6 months after infection or 6 months after the booster
114 injection from 9 individuals in each group of patients.

115 Anti-RBD IgG levels were measured using the bioMérieux Vidas SARS-CoV-2 IgG diagnosis kit
116 according to manufacturer's recommendations and expressed in binding antibody unit (BAU)
117 /mL. The dotted line represents the threshold of positivity (≥ 20.33 BAU/mL) (**Panel A**).

118 Anti-S1 IgA levels were measured using an ELISA test as previously described [5] and
119 expressed in µg/mL. The dotted line represents the positivity threshold (≥ 0.0018 µg/mL)
120 (**Panel B**).

121 Neutralizing antibody titers against live SARS-CoV-2 isolates using a 50% plaque reduction
122 neutralization test ($PRNT_{50}$), as previously described [5]. The isolates used for these
123 experiments were 19A, Delta, Omicron BA.1, BA.4, and BA.5; their GISAID accession numbers
124 are EPI_ISL_1707038, EPI_ISL_1904989, EPI_ISL_7608613, EPI_ISL_12396843, and
125 EPI_ISL_12852091, respectively. The dotted line represents the positivity threshold (titer ≥
126 20) (**Panel C**).

127 Data are represented as box and whiskers plot; in each plot, the dots indicate individual
128 samples, the upper and lower limits of the box plot represent the interquartile [IQR] range
129 and the middle line represents the median. A Kruskal-Wallis test followed by Dunn's multiple
130 comparison tests were performed to assess differences between the three groups.


A
P=0.008
P=0.002
Anti-RBD IgG levels (BAU/mL)
10000
1000
100
10
B
P=0.004
P<0.001
Anti-S1 IgA (µg/mL)
10
1
0.1
0.01
0.001
C
P=0.002
P=0.005
P=0.003
P=0.02
P=0.005
P=0.001
P<0.001
P<0.001
P<0.001
P<0.001
Neutralizing antibody titers (PRNT50)
8192
4096
2048
1024
512
256
128
64
32
16
8
19A
Delta
BA.1
BA.4
BA.5
Delta-BA.1 co-infection
BA.1 infection
COVID-19-naive
fully vaccinated